Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

INDIANAPOLIS, May 15, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically... Biopharmaceuticals, Neurology Eli Lilly, cluster headache, galcanezumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news